THRX Advisory Commitee Meeting 03/07/2013

THRX March 7, 2013 8:00 a.m. to 5:00 p.m.   FDA White Oak Campus Building 31 The Great Room (Rm. 1503) White Oak Conference Center 10903 New Hampshire Avenue Silver Spring, Maryland Agenda The committee will discuss the new drug application (NDA) 204275 for fluticasone furoate and vilanterol dry powder inhaler (proposed tradename BREO ELLIPTA), sponsored by GlaxoSmithKline, for the long-term maintenance treatment of airflow obstruction and for reducing exacerbations in patients with chronic obstructive pulmonary disease.